BSE filing, NSE: RELIGARE. Summary written from the filing by ALFA Finder's alert engine.
Religare Enterprises Ltd: key numbers
- Share price
- ₹232.77
- Market cap
- ₹8,025 Cr
- Revenue (annual)
- ₹8,459 Cr
- Net profit (annual)
- ₹85.96 Cr
- P/E (TTM)
- 345.9×Sector 20.3×
- Promoter holding
- 31.26%+0.70% QoQ
- FII holding
- 9.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Religare Enterprises Ltd
All →Religare Enterprises Credit Rating
Religare Enterprises disclosed that CRISIL upgraded credit ratings for its subsidiary Religare Broking's Rs. 500 Crore bank facilities. Long-term rating moved to BBB+/Stable and short-term to A2+.
Religare Enterprises Debt & Borrowing: ₹150 Cr
Care Health Insurance, a material subsidiary of Religare, allotted listed subordinated debentures worth ₹150 Crore at a 10.50% coupon. The debentures mature in 2036, callable after five years.
- Value
- ₹150.0 Cr
Religare Enterprises Management Change
Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.
Religare Enterprises Other Announcement
Religare Enterprises has filed its quarterly shareholding pattern for the period ending September 30, 2026, as per SEBI Regulation 31(1)(b).
Religare Enterprises Employee Stock Options
Religare Enterprises allotted 22,000 equity shares upon exercise of employee stock options. This allotment increases the company's issued and paid-up equity capital.
Religare Enterprises Management Change
Religare disclosed Mr. Gaurav Sharma as CTO of subsidiary Religare Finvest, effective October 6, 2026. He brings ~30 years of fintech experience from IIFL and L&T Financial.
Other board meeting date announcements
All →B.D. Industries (Pune) Board Meeting Date
B. D. Industries (Pune) will hold a board meeting on 14 November 2026 to consider unaudited standalone and consolidated half-year results. The agenda items are proposed only and no decision has been taken yet.
Health X Platform Board Meeting Date
Health X Platform will hold a board meeting on 14 November 2026 to approve quarterly results. Trading window stays closed until 48 hours after declaration.
Exato Technologies Board Meeting Date
Board meeting set for November 14, 2026 to approve half-year results and an ESOP scheme. Trading window closed from October 1.
Astal Laboratories Board Meeting Date
Astal Laboratories will hold a board meeting on 13 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the meeting.
Brainbees Solutions Board Meeting Date
Brainbees Solutions will hold a board meeting on November 14, 2026 to approve September 2026 quarter and half-year results. Trading window stays closed until November 16.
Senco Gold Board Meeting Date
Senco Gold schedules a board meeting on 13 November 2026 to consider unaudited quarterly and half-year results. The trading window stays closed until 48 hours after declaration.